The predictive value of digoxin and furosemide treatment for identifying patients receiving treatment for congestive heart failure (CHF), the use of angiotensin-converting-enzyme (ACE) inhibitors in this population, and the ability of a pharmacist outreach program to address underutilization of ACE inhibitors were studied. All physicians and owner-managers of community pharmacies on Newfoundland's Avalon Peninsula were asked to participate in the study. Pharmacists who agreed to participate were asked to list patients of the participating physicians with prescriptions for (1) furosemide and digoxin with and without an ACE inhibitor or angiotensin II-receptor inhibitor and (2) an ACE inhibitor. Physicians were visited by a pharmacist and asked whether each of their patients receiving digoxin and furosemide was being treated for CHF and to identify further cases of CHF among their patients receiving an ACE inhibitor. Intervention-group physicians received academic detailing on the use and dosage of ACE inhibitors and angiotensin II-receptor inhibitors for CHF. Both groups were reinterviewed after three months to establish what if any changes in therapy had occurred for each patient discussed during the first visit. The positive predictive value of digoxin and furosemide treatment for identifying patients receiving treatment for CHF was 94%. Seventy-six percent of patients identified by physicians as CHF patients who were taking digoxin and furosemide were treated with an ACE inhibitor. Thirty-six percent of patients treated with an ACE inhibitor for CHF received the targeted dosage. Four physicians stated that the outreach visit influenced their prescribing, but there was no significant difference in ACE inhibitor prescribing between the intervention and control groups. A pharmacist outreach program involving the use of prescription records and academic detailing did not affect prescribing or dosages of ACE inhibitors but demonstrated value as a quality assurance tool.

 

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. G. McDonald, S. R. Majumdar, J. L. Mahon, and J. A. Johnson The Effectiveness of {beta}-Blockers After Myocardial Infarction in Patients With Type 2 Diabetes Diabetes Care, September 1, 2005; 28(9): 2113 - 2117. [Abstract] [Full Text] [PDF]

				T. Jaarsma Health care professionals in a heart failure team Eur J Heart Fail, March 16, 2005; 7(3): 343 - 349. [Abstract] [Full Text] [PDF]

				D. T. Eurich, S. R. Majumdar, R. T. Tsuyuki, and J. A. Johnson Reduced Mortality Associated With the Use of ACE Inhibitors in Patients With Type 2 Diabetes Diabetes Care, June 1, 2004; 27(6): 1330 - 1334. [Abstract] [Full Text] [PDF]